Finch Therapeutics Group Statistics
Total Valuation
Finch Therapeutics Group has a market cap or net worth of 17.34 million. The enterprise value is 30.30 million.
| Market Cap | 17.34M |
| Enterprise Value | 30.30M |
Important Dates
The next estimated earnings date is Monday, March 24, 2025.
| Earnings Date | Mar 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Finch Therapeutics Group has 1.61 million shares outstanding. The number of shares has increased by 0.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.61M |
| Shares Change (YoY) | +0.41% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 44.20% |
| Owned by Institutions (%) | 0.00% |
| Float | 896,023 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.14 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.68 |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 2.04.
| Current Ratio | 3.87 |
| Quick Ratio | 3.59 |
| Debt / Equity | 2.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.61 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -67.28% and return on invested capital (ROIC) is -24.09%.
| Return on Equity (ROE) | -67.28% |
| Return on Assets (ROA) | -21.89% |
| Return on Capital (ROIC) | -24.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -14.17M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +203.37% in the last 52 weeks. The beta is 1.33, so Finch Therapeutics Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +203.37% |
| 50-Day Moving Average | 11.70 |
| 200-Day Moving Average | 6.60 |
| Relative Strength Index (RSI) | 40.64 |
| Average Volume (20 Days) | 2,777 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.69M |
| Pretax Income | -14.17M |
| Net Income | -14.17M |
| EBITDA | -19.51M |
| EBIT | -19.69M |
| Earnings Per Share (EPS) | -8.82 |
Balance Sheet
The company has 16.04 million in cash and 28.99 million in debt, giving a net cash position of -12.95 million or -8.07 per share.
| Cash & Cash Equivalents | 16.04M |
| Total Debt | 28.99M |
| Net Cash | -12.95M |
| Net Cash Per Share | -8.07 |
| Equity (Book Value) | 14.22M |
| Book Value Per Share | 8.85 |
| Working Capital | 12.82M |
Cash Flow
In the last 12 months, operating cash flow was -18.06 million and capital expenditures 14,000, giving a free cash flow of -18.04 million.
| Operating Cash Flow | -18.06M |
| Capital Expenditures | 14,000 |
| Free Cash Flow | -18.04M |
| FCF Per Share | -11.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Finch Therapeutics Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.41% |
| Shareholder Yield | -0.41% |
| Earnings Yield | -81.70% |
| FCF Yield | -104.03% |
Stock Splits
The last stock split was on June 12, 2023. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | Jun 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
Finch Therapeutics Group has an Altman Z-Score of -12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12 |
| Piotroski F-Score | n/a |